• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗体导向尿激酶:一种特异性纤溶药物。

Antibody-directed urokinase: a specific fibrinolytic agent.

作者信息

Bode C, Matsueda G R, Hui K Y, Haber E

出版信息

Science. 1985 Aug 23;229(4715):765-7. doi: 10.1126/science.4023710.

DOI:10.1126/science.4023710
PMID:4023710
Abstract

A specific fibrinolytic agent was synthesized by covalently coupling urokinase to a monoclonal antibody that was fibrin-specific and did not cross-react with fibrinogen. The antibody was raised against a synthetic peptide representing the seven amino-terminal residues of the beta chain of human fibrin. The urokinase-antifibrin conjugate retained the original binding specificity of the antibody and showed 100-fold increased fibrinolysis in vitro when compared to unmodified urokinase. The presence of human fibrinogen at plasma concentration did not influence these properties.

摘要

通过将尿激酶与一种纤维蛋白特异性且不与纤维蛋白原交叉反应的单克隆抗体共价偶联,合成了一种特异性纤溶酶原激活剂。该抗体是针对代表人纤维蛋白β链七个氨基末端残基的合成肽产生的。与未修饰的尿激酶相比,尿激酶 - 抗纤维蛋白缀合物保留了抗体原有的结合特异性,并且在体外显示出纤溶活性提高了100倍。血浆浓度的人纤维蛋白原的存在不影响这些特性。

相似文献

1
Antibody-directed urokinase: a specific fibrinolytic agent.抗体导向尿激酶:一种特异性纤溶药物。
Science. 1985 Aug 23;229(4715):765-7. doi: 10.1126/science.4023710.
2
Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin.一种抗体-尿激酶偶联物的特性。一种靶向纤维蛋白的纤溶酶原激活剂。
J Biol Chem. 1987 Aug 5;262(22):10819-23.
3
Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.与抗纤维蛋白单克隆抗体结合可增强组织型纤溶酶原激活剂在体外的纤溶活性。
Biochemistry. 1988 Feb 23;27(4):1153-7. doi: 10.1021/bi00404a012.
4
Thrombolysis by a fibrin-specific antibody Fab'-urokinase conjugate.纤维蛋白特异性抗体Fab'-尿激酶偶联物介导的溶栓作用。
J Mol Cell Cardiol. 1987 Apr;19(4):335-41. doi: 10.1016/s0022-2828(87)80578-3.
5
Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.一种由抗纤维蛋白单链抗体和低分子量尿激酶组成的重组纤溶酶原激活剂的构建与表征
J Thromb Haemost. 2004 May;2(5):797-803. doi: 10.1111/j.1538-7836.2004.00697.x.
6
A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase.双特异性抗体增强单链尿激酶的纤溶活性。
Biochemistry. 1990 Jul 10;29(27):6374-8. doi: 10.1021/bi00479a005.
7
Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
Ann N Y Acad Sci. 1992 Dec 4;667:428-30. doi: 10.1111/j.1749-6632.1992.tb51644.x.
8
Hybrid molecules: insights into plasminogen activator function.杂合分子:对纤溶酶原激活物功能的见解
Mol Biol Med. 1991 Apr;8(2):245-55.
9
Chemical coupling of a monoclonal antisurfactant protein-B antibody to human urokinase for targeting surfactant-incorporating alveolar fibrin.单克隆抗表面活性蛋白-B抗体与人尿激酶的化学偶联,用于靶向结合表面活性剂的肺泡纤维蛋白。
Bioconjug Chem. 2002 Jul-Aug;13(4):804-11. doi: 10.1021/bc0255081.
10
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.一种针对人纤维蛋白和尿激酶型纤溶酶原激活剂的双特异性单克隆抗体在体外和体内增强血凝块溶解作用。
Thromb Haemost. 1991 Dec 2;66(6):684-93.

引用本文的文献

1
Translational initiatives in thrombolytic therapy.溶栓治疗的转化研究。
Front Med. 2017 Mar;11(1):1-19. doi: 10.1007/s11684-017-0497-8. Epub 2017 Mar 2.
2
Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.通过人补体受体1将组织纤溶酶原激活剂负载于循环红细胞上进行预防性纤维蛋白溶解。
Blood. 2006 Sep 15;108(6):1895-902. doi: 10.1182/blood-2005-11-012336. Epub 2006 May 30.
3
Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.
将PECAM-1单链可变抗体片段(scFv)与尿激酶原融合的重组构建体靶向内皮细胞,有助于在肺血管系统中进行预防性溶栓。
Blood. 2005 Dec 15;106(13):4191-8. doi: 10.1182/blood-2005-05-2002. Epub 2005 Sep 6.
4
Genetic identification of antigens exposed in damaged endothelial cells as laminin-binding proteins.将受损内皮细胞中暴露的抗原鉴定为层粘连蛋白结合蛋白的遗传学方法。
Clin Exp Immunol. 1998 May;112(2):255-61. doi: 10.1046/j.1365-2249.1998.00567.x.
5
Thrombolytic therapy in acute myocardial infarction--selected recent developments.
Ann Hematol. 1994 Oct;69(4):S35-40. doi: 10.1007/BF02215957.
6
Thrombolytic agents in development.正在研发的溶栓剂。
Drugs. 1995 Jul;50(1):29-42. doi: 10.2165/00003495-199550010-00003.
7
Selective cytotoxicity of an oxygen-radical-generating enzyme conjugated to a monoclonal antibody.与单克隆抗体偶联的产生活性氧自由基的酶的选择性细胞毒性。
Clin Exp Immunol. 1988 Jul;73(1):128-33.
8
What is established in thrombolytic therapy of acute myocardial infarction? Pharmacological approaches.急性心肌梗死溶栓治疗中已确立的内容是什么?药理学方法。
Cardiovasc Drugs Ther. 1988 May;2(1):121-5. doi: 10.1007/BF00054262.
9
New strategies in the development of thrombolytic agents.溶栓药物开发的新策略。
Blut. 1988 Oct;57(4):147-62. doi: 10.1007/BF00319543.
10
Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.抗体增强溶栓作用:组织纤溶酶原激活剂在体内的靶向作用
Proc Natl Acad Sci U S A. 1987 Nov;84(21):7659-62. doi: 10.1073/pnas.84.21.7659.